2018
DOI: 10.1007/s40121-018-0206-1
|View full text |Cite
|
Sign up to set email alerts
|

Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada

Abstract: IntroductionPneumococcal conjugate vaccines (PCVs) have been available in Canada since 2001, with 13-valent PCV (PCV13) added to the infant routine immunization program throughout all Canadian provinces by 2011. The use of PCVs has dramatically reduced the burden of pneumococcal disease in Canada. As a result, decision-makers may consider switching from a more costly, higher-valent vaccine to a lower-cost, lower-valent vaccine in an attempt to allocate funds for other vaccine programs. We assessed the health a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
40
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 30 publications
(41 citation statements)
references
References 50 publications
1
40
0
Order By: Relevance
“…The findings obtained by modeling the clinical and economic impact of pediatric pneumococcal conjugate vaccine programs in Italy are consistent with those of several studies [16,17] that applied a similar forecasting decision-analytic model in the Canadian and Mexican contexts and with the real experience of Belgium (Flanders and Wallonia) where the switch caused a ten-fold increase in the number of 19A pneumococcal disease isolates from 2015 to 2017 [13].…”
Section: Discussionsupporting
confidence: 86%
See 1 more Smart Citation
“…The findings obtained by modeling the clinical and economic impact of pediatric pneumococcal conjugate vaccine programs in Italy are consistent with those of several studies [16,17] that applied a similar forecasting decision-analytic model in the Canadian and Mexican contexts and with the real experience of Belgium (Flanders and Wallonia) where the switch caused a ten-fold increase in the number of 19A pneumococcal disease isolates from 2015 to 2017 [13].…”
Section: Discussionsupporting
confidence: 86%
“…Although some other studies describe the health and economic impact of switching the infant vaccination program from 13-to 10-valent PCV [16][17][18], this analysis estimates the impact based on the epidemiology and serotype dynamics specific to PCV experience in Italy. In order to better define the serotype dynamics, data from the most sensitive regional surveillance systems were used and were considered representative of the incidence rate across the entire country, as no potential bias was knowingly introduced.…”
Section: Discussionmentioning
confidence: 99%
“…The Mexico perspective was also the second publication of this methodology, for which there are additional data summarizing particular assumptions available for the reader. 9 In our model, both PCV10 and PCV13 largely eliminate disease caused by the 10 common serotypes. As already discussed above, the difference in the 0-2 age group is driven primarily by replacement of 19A disease in the PCV10 arm, which was has been observed in numerous countries using PCV10.…”
Section: Pcv13 Vaccine Effectiveness Against Serotypementioning
confidence: 92%
“…An existing pneumococcal disease forecasting model was adapted. 14 The model was built using real-world pre-and post-PCV surveillance data from PCV10 (e.g. Finland and the Netherlands) and PCV13 (e.g.…”
Section: Model Designmentioning
confidence: 99%